- Home
- NGNE vs EM Comparison
NGNE vs EM Comparison
Compare NGNE & EM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- EM
- Stock Information
- Founded
- NGNE 2003
- EM 2017
- Country
- NGNE United States
- EM China
- Employees
- NGNE N/A
- EM N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- EM Other Consumer Services
- Sector
- NGNE Health Care
- EM Consumer Discretionary
- Exchange
- NGNE Nasdaq
- EM Nasdaq
- Market Cap
- NGNE 251.9M
- EM 273.0M
- IPO Year
- NGNE N/A
- EM 2021
- Fundamental
- Price
- NGNE $21.83
- EM $1.10
- Analyst Decision
- NGNE Buy
- EM
- Analyst Count
- NGNE 6
- EM 0
- Target Price
- NGNE $39.83
- EM N/A
- AVG Volume (30 Days)
- NGNE 224.0K
- EM 37.1K
- Earning Date
- NGNE 05-09-2025
- EM 06-17-2025
- Dividend Yield
- NGNE N/A
- EM N/A
- EPS Growth
- NGNE N/A
- EM N/A
- EPS
- NGNE N/A
- EM N/A
- Revenue
- NGNE $925,000.00
- EM $259,541,587.00
- Revenue This Year
- NGNE N/A
- EM $3.30
- Revenue Next Year
- NGNE N/A
- EM $5.26
- P/E Ratio
- NGNE N/A
- EM N/A
- Revenue Growth
- NGNE N/A
- EM N/A
- 52 Week Low
- NGNE $6.88
- EM $0.50
- 52 Week High
- NGNE $74.49
- EM $1.17
- Technical
- Relative Strength Index (RSI)
- NGNE 62.53
- EM 53.85
- Support Level
- NGNE $16.62
- EM $1.06
- Resistance Level
- NGNE $18.90
- EM $1.11
- Average True Range (ATR)
- NGNE 2.06
- EM 0.02
- MACD
- NGNE 0.38
- EM 0.00
- Stochastic Oscillator
- NGNE 60.81
- EM 58.33
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About EM Smart Share Global Limited
Smart Share Global Ltd is a consumer tech company providing mobile device charging services through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Geographically, the company generates revenue from the PRC. The company has two segments, the mobile device charging segment and the PV business segment. The company generates the majority of its revenue from the mobile device charging segment.